SHENZHEN, China, Jan. 12 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.
Terry Yuan, HTDS President, said, "In our efforts to maximize shareholder value, we believe that the distribution of the Hiru shares will benefit our shareholders." The Hiru stock will be distributed to shareholders of record on a date to be set by the company in consultation with FINRA. The Hiru shares will be restricted and not immediately freely tradable. HTDS shareholders holding HTDS on the record date will not be required to take any action to receive the Hiru common shares on the distribution date. Consummation of the special onetime distribution is subject to the approval of FINRA.
In other company news and events, the company continues to work with Pink Sheets who is not a registered SRO to have the toon type skull and bones icon removed from HTDS quote. (SRO see http://en.wikipedia.org/wiki/Self-regulatory_organization) The company management feels that Pink Sheets should remain neutral and not punish any company with the "traffic signals" once the company has identified a naked short seller publicly or when the company issues a forward guidance report to its shareholders. Now, it appears that finally FINRA is taking notice of Pink Sheets actions on many levels http://www.sec.gov/rules/sro/finra/2009/34-60999.pdf. The company disagrees with many assertions made by Pink Sheets as self serving http://brokeandbroker.com/images/PinkSheetProp.pdf
The company will shortly order a NOBO list and a DTC Run from its transfer agent to establish where and how some market makers continue to offer HTDS stock for sale and what instruments are being used to hedge these sales. The company repeats again that its security is grossly undervalued and places a valuation on its share price in the several penny price range. The company vows to do all it can to see these values returned to its shareholder base.
All of this comes on a heel of the company signing major contracts Internationally, a 1 time special distribution and some previously announced pending contracts, including possible merger discussion with a USA based nutrient replenishing company in a Health Care, Surgical Wound Healing Trauma Victims Diabetics sector.
To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
SOURCE Hard to Treat Diseases